1. Home
  2. RNXT vs LSTA Comparison

RNXT vs LSTA Comparison

Compare RNXT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNXT
  • LSTA
  • Stock Information
  • Founded
  • RNXT 2012
  • LSTA 1980
  • Country
  • RNXT United States
  • LSTA United States
  • Employees
  • RNXT N/A
  • LSTA N/A
  • Industry
  • RNXT Biotechnology: Pharmaceutical Preparations
  • LSTA Misc Health and Biotechnology Services
  • Sector
  • RNXT Health Care
  • LSTA Health Care
  • Exchange
  • RNXT Nasdaq
  • LSTA Nasdaq
  • Market Cap
  • RNXT 31.6M
  • LSTA 31.2M
  • IPO Year
  • RNXT 2021
  • LSTA N/A
  • Fundamental
  • Price
  • RNXT $1.46
  • LSTA $2.64
  • Analyst Decision
  • RNXT Strong Buy
  • LSTA Strong Buy
  • Analyst Count
  • RNXT 2
  • LSTA 1
  • Target Price
  • RNXT $6.50
  • LSTA $15.00
  • AVG Volume (30 Days)
  • RNXT 108.8K
  • LSTA 72.4K
  • Earning Date
  • RNXT 03-31-2025
  • LSTA 02-27-2025
  • Dividend Yield
  • RNXT N/A
  • LSTA N/A
  • EPS Growth
  • RNXT N/A
  • LSTA N/A
  • EPS
  • RNXT N/A
  • LSTA N/A
  • Revenue
  • RNXT N/A
  • LSTA N/A
  • Revenue This Year
  • RNXT N/A
  • LSTA N/A
  • Revenue Next Year
  • RNXT N/A
  • LSTA N/A
  • P/E Ratio
  • RNXT N/A
  • LSTA N/A
  • Revenue Growth
  • RNXT N/A
  • LSTA N/A
  • 52 Week Low
  • RNXT $0.77
  • LSTA $2.19
  • 52 Week High
  • RNXT $1.86
  • LSTA $4.20
  • Technical
  • Relative Strength Index (RSI)
  • RNXT 58.08
  • LSTA 42.17
  • Support Level
  • RNXT $1.32
  • LSTA $2.45
  • Resistance Level
  • RNXT $1.40
  • LSTA $2.74
  • Average True Range (ATR)
  • RNXT 0.11
  • LSTA 0.32
  • MACD
  • RNXT 0.00
  • LSTA -0.05
  • Stochastic Oscillator
  • RNXT 39.47
  • LSTA 16.48

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

Share on Social Networks: